锐客网

  1. 首页 > 生活杂烩 > 健康 > >

肿瘤|外媒：中国的免疫肿瘤学试验增长最快

▲全球视野 本土思考
肿瘤|外媒：中国的免疫肿瘤学试验增长最快
文章图片

中国的此类试验数量猛增了七倍，达到135次 。
根据GlobalData的数据，中国在2020年启动的针对八种主要市场的PD-1/ PD-L1靶向组合免疫肿瘤疗法研究的临床试验中，增长最快 。
在由行业发起的针对PD-1 / PD-L1靶向联合疗法的临床试验中，美国已成为领先的市场，并进行了249项新试验，其次是中国的135项试验 。
这对中国而言是增加了七倍多，而在美国，这一年中启动的试验数量仅略高于2017年 。
GlobalData的血液学和肿瘤学分析师Ufuk Ezer评论道：“这可能归因于新兴的国内PD-1 / PD-L1抑制剂市场，以及中国行业法规和政策的整体转型，推动了肿瘤学的研究与开发 。”
在欧洲主要国家，同一时期此类试验的增长率大部分与美国的增长率相符，而在日本，以美国为基准，年变化幅度较小 。
在2017年至2019年之间，针对PD-1 / PD-L1靶向联合疗法的临床试验数量激增，并在2020年继续增长，尽管其速度明显放缓，原因可能是全球COVID-19大流行 。
考虑到2017-2020年所有针对PD-1 / PD-L1靶向药物的临床试验，联合试验占84％以上 。报告指出，这显示出对这类检查点抑制剂的联合疗法而非单一疗法的兴趣日益浓厚 。
“以生物标志物为主导的联合疗法以及诸如双重检查点靶向或更复杂的免疫疗法联合等新的治疗方法在癌症治疗中正处于兴起，” Ezer补充说 。＊
China hits fastest growth in immuno-oncology trials
The number of such trials in the country surged sevenfold to 135.
China has recorded the highest growth in the number of clinical trials initiated to investigate PD-1/PD-L1 targeted combination immuno-oncology therapies across the eight major markets (8MM) in 2020, according to GlobalData.
The US emerged as the leading market in industry-sponsored initiated clinical trials for PD-1/PD-L1 targeted combination therapies with 249 new trials, followed by China with 135 trials.
This represents a more than sevenfold increase for China, whereas in the US the number of initiated trials during the year was only slightly higher than 2017.
“This could be attributed to the emerging domestic PD-1/PD-L1 inhibitor market, as well as the overall transformation in the country’s industry regulations and policies, driving research and development in oncology,” GlobalData's hematology and oncology analyst Ufuk Ezer commented.
In major European countries, the growth rates of such trials during the same period were mostly in line with the rates in the US, whereas in Japan the yearly changes were less significant when benchmarked with the US.
Between 2017 and 2019, the number of clinical trials initiated for PD-1/PD-L1 targeted combination therapies soared, which continued in 2020, albeit with a significantly slower rate possibly due to the global COVID-19 pandemic.
Considering all initiated clinical trials featuring PD-1/PD-L1 targeting drugs in 2017-2020, combination trials accounted for more than 84%. This shows a growing interest in combinations rather than monotherapies of this class of checkpoint inhibitors, the report noted.
【肿瘤|外媒：中国的免疫肿瘤学试验增长最快】“Biomarker-led combination therapies, and new treatment modalities such as dual checkpoint targeting or more sophisticated immunotherapy combinations are on the horizon in cancer care,” Ezer added.

    推荐阅读


    上一篇：免疫|免疫治疗联合化疗，这个晚期患者的肿瘤明显消退！

    下一篇：阿司匹林|硫酸氢氯吡格雷能取代阿司匹林吗？两种药有什么区别？